Oric Pharmaceuticals (ORIC) FY Conference Transcript

Summary of Oric Pharmaceuticals (ORIC) FY Conference Call Company Overview - Company: Oric Pharmaceuticals (ORIC) - Industry: Clinical stage oncology, focusing on small molecule treatments for solid tumors, specifically prostate cancer, lung cancer, and breast cancer [2][3] Key Programs and Pipeline - ORIC-944: An allosteric PRC2 inhibitor in combination with AR inhibitors for prostate cancer [3][4] - ORC-114: A brain-penetrant EGFR HER2 exon 20 inhibitor for non-small cell lung cancer mutations [4][63] Clinical Development and Data - Upcoming Studies: Plans to initiate two Phase III studies in 2026 for ORIC-944 and ORC-114 [4][88] - Recent Data: Initial data from a Phase 1b study showed a PSA 50 response of 47% and a PSA 90 response of 24% in combination with AR inhibitors, which is favorable compared to Pfizer's data [18][20] - Safety Profile: ORIC-944 demonstrated a lower incidence of treatment-related adverse events compared to Pfizer's PRC2 inhibitor, with a diarrhea rate of 53% and only one grade three event [19][20] Competitive Landscape - Market Opportunity: Prostate cancer represents a significant market with approximately 40,000 to 50,000 patients in metastatic CRPC annually [34] - Comparison with Competitors: ORIC-944 aims to differentiate itself from Pfizer's mebrometostat by having a longer half-life (20 hours vs. 2 hours) and a potentially better safety profile [12][33][34] - Other Competitors: Awareness of several other PRC2 inhibitors in development, including those from Novartis and various companies in China, which may not be optimized for prostate cancer [40][41] Future Expectations and Updates - Next Updates: Anticipated updates on ORIC-944 in the second half of 2025, with a focus on PSA response and safety [51][56] - Phase III Study Timeline: Expected to start the Phase III study for ORIC-944 in the first half of 2026 [57][88] Financial Position - Recent Financing: Raised $125 million in a PIPE financing, extending cash runway into the second half of 2027 [88] - Cash Management: The cash runway includes funding for both assets and assumes no strategic partnerships, covering all costs associated with the upcoming Phase III studies [88] Additional Insights - Combination Studies: ORIC-114 is being studied in combination with amivantamab, which may provide synergistic effects due to its unique mechanism of action [80][84] - Patient Population: ORIC's studies allow for patients with active metastases, which is a differentiating factor compared to other trials that have stringent inclusion criteria [67][72] This summary encapsulates the key points discussed during the conference call, highlighting Oric Pharmaceuticals' strategic focus, clinical advancements, competitive positioning, and financial outlook.